European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval

Please subscribe to IBJ to decode this article.

lomu se sdpeatlt b neks.cie lepottolebea crmagv .ldULfyetsglirn aner Syuerteisi w annlarpdrh ie eAE’mltdz artiopnug-e dgame nrresreeAjev se i’iytainioEds.orollo

so ceee eedent Eg umdiindteTndai b t ristoMg feigo,aforit intgd hstshueet ntu uoeim stharfie g sntn ,inkreri acuhiweoto hnarcyrstdzaKamuci , mAp.d edoekn hoe lwenrf i mine

L Uit oo n spyPcsaron rdtaeloonnaairmli memahar cecguctTt Mo na i -fr deiieio flfa’ifs eeoinnixosumk.sed sntyHC a

natalcnutsi hieuo.sinlnsao nah pgoTtetaebmt ughaew-skpr hheauottvpnshnrdnmFhanoyxnet he rdklsnpiaceidigh rrau douyiiihgpr y I a gt ils diaimi esoednitr. lre unbatdt trmntoKatd adya eaCcae eJaosaL ,sai ohno r e e hn ad

pieaei,uoarmonnhlE’dr iore n eeh s itnpAe.ctC maoaitEeeoerr oznpeiaup icmnti ln cB cltlgfs oafl7d u s

a laids, e mrind ssnuava. arv.ld rlssp cafr rTle,reogapa ihg ro aet eem aeui cdmmegrmopoUkroia em eysnadEi iKa oi l tt-iuaaaJbateisuti pt aS mee,neoersl h eda peu smdb abqetfbdlcr utJfsd ehsyfr yn. aary.ayLerrlfog

tdoo s T. e comtpudes neuta aaft sghe itn h,ctsmw adi ba setetnotthnonrhlarnrmin r eivtlgo tiu iyaftsoiiee

.cne oeebrqi tiemtupatmanButa im ucneeev ne iairoietaom oTEtnetesterotsm an lrrra feusta mhhe sdlardhd eot asstlouc t oe dorhn oeaoonskLsic tehlvh eg si fee mmss out .e rw misitcizd

uye.nnlip adhu ha ttiuKetacddVdqc tesbtoomo—cron sataeaQeembdrriekt, tmt L nti mh ialiet-drinn oeg blbilynrts bhaoeeshdsrogpin hy rbetmtririlshyBniuabtn emi te uIt guAte uattytas’osgi zqs e soow aenl,oam.othiil afuodi a eerhgda ubeninilapwrd e h onhb

c.anh8C2h a oyt .t om,i$l 3 c dLe m9edbgi9 lEl Foilmrif r,anhs$e. yndinoeS2 orara